{"entity":{"id":"bexobrutideg","kind":"drug","name":"Bexobrutideg","aka":[],"tldr":"Bexobrutideg is an experimental protein degrader from Nurix Therapeutics in phase 3 trials for chronic lymphocytic leukaemia, aimed at BTK (Bruton tyrosine kinase).","summary":"Bexobrutideg (NX-5948) is a protein degrader developed by Nurix Therapeutics. Its target is BTK (Bruton tyrosine kinase) (the sponsor names BTK (Bruton's tyrosine kinase)). The sponsor states: NX-5948 is an oral, CNS-penetrant BTK degrader that removes the BTK protein rather than only inhibiting its activity, which the sponsor states may help overcome kinase-domain and scaffolding-mediated resistance mutations. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07516093 (Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL), in chronic lymphocytic leukaemia. The largest, NCT07516093, plans to enrol 620 participants with primary completion expected 2029-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Bexobrutideg","url":"https://clinicaltrials.gov/search?intr=Bexobrutideg"},{"label":"Sponsor pipeline page","url":"https://www.nurixtx.com/pipeline/"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":["btk"],"drugs":[],"companies":["nurix"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07516093","nct07520006","nct07221500"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"NX-5948","modality":"protein degrader","mechanism":"NX-5948 is an oral, CNS-penetrant BTK degrader that removes the BTK protein rather than only inhibiting its activity, which the sponsor states may help overcome kinase-domain and scaffolding-mediated resistance mutations.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bexobrutideg/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"target":[{"id":"btk","kind":"target","name":"BTK (Bruton tyrosine kinase)","route":"/targets/btk/"}],"company":[{"id":"nurix","kind":"company","name":"Nurix Therapeutics","route":"/companies/nurix/"}],"trial":[{"id":"nct07221500","kind":"trial","name":"A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)","route":"/trials/nct07221500/"},{"id":"nct07520006","kind":"trial","name":"Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies","route":"/trials/nct07520006/"},{"id":"nct07516093","kind":"trial","name":"Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL","route":"/trials/nct07516093/"}]}}